AS-601811

AS-601811
Clinical data
Other namesAS-601811; AS601811
Routes of
administration		Oral
Drug class5α-Reductase inhibitor
ATC code
  • None
Identifiers
  • 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC15H17NO
Molar mass227.307 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C
  • InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3
  • Key:SNEPAAKJPPNOQM-UHFFFAOYSA-N

AS-601811 is a 5α-reductase inhibitor of type 1 of the enzyme which was under development for the treatment of acne, benign prostatic hyperplasia, hirsutism, male-pattern baldness, and prostate cancer but was never marketed. It is taken orally. The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was being developed by Merck Serono.

See also

References

  1. 1 2 3 4 5 "AS 601811". AdisInsight. 12 March 2008. Retrieved 23 October 2025.
  2. 1 2 Voegeli R, Zouboulis CC, Elsner P, Schreier T (17 May 2007). "5a-Reductase and Its Inhibitors". In Webster GF, Rawlings AV (eds.). Acne and Its Therapy. CRC Press. pp. 181–216. doi:10.3109/9781420018417-18. ISBN 978-0-429-16389-0. Retrieved 23 October 2025.